25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.

A Lipplaa, R Fernandes, A Marshall, Paul Lorigan, J Dunn, KA Myers, E Barker, J Newton-Bishop, MR Middleton, PG Corrie

Research output: Contribution to journalArticlepeer-review

Abstract

Background Studies evaluating a relationship of vitamin D in patients with primary melanoma have consistently identified an inverse correlation with Breslow thickness, but an inconsistent impact on survival. Vitamin D in later stages of melanoma has been less studied. Methods Vitamin D was measured in serum from 341 patients with resected stage IIB–IIIC melanoma recruited to the AVAST-M adjuvant melanoma randomised trial, collected prior to randomisation, then at 3 and 12 months. Vitamin D levels were compared with patient demographics, known melanoma prognostic factors, disease-free interval (DFI) and overall survival (OS). Results A total of 73% patients had stage III melanoma, 32% were enroled (and therefore tested) >1 year after primary melanoma diagnosis. Median pre-randomisation vitamin D level was 56.5 (range 12.6–189.0 nmol/L). Vitamin D levels did not significantly vary over 12 months (p = 0.24). Individual pre-randomisation vitamin D levels did not differ significantly for Breslow thickness, tumour ulceration, or disease stage. Neither did pre-randomisation vitamin D predict for DFI (HR = 0.98 per 10 nmol/L increase; 95% confidence interval (CI) 0.93–1.04, p = 0.59) or OS (HR = 0.96 per 10 nmol/L increase, 95% CI 0.90–1.03, p = 0.31). For stage II patients, DFI improved with higher pre-randomisation vitamin D levels for those on bevacizumab (HR = 0.74 per 10 nmol nmol/L increase; 95% CI 0.56–0.97), but not for the observation arm (HR = 1.07 per 10 nmol/L increase; 95% CI 0.85–1.34). Conclusions In this stage II/III melanoma cohort, vitamin D did not correlate with known prognostic markers, nor predict for DFI or OS, but there was some evidence of benefit for patients with stage II disease treated with bevacizumab.
Original languageEnglish
Article numberPMID: 30033445
Pages (from-to)793-800
Number of pages8
JournalBritish Journal of Cancer
Volume119
Issue number7
Early online date23 Jul 2018
DOIs
Publication statusPublished - 2 Oct 2018

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of '25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.'. Together they form a unique fingerprint.

Cite this